While trimethoprim-sulfamethoxazole is considered first-line therapy for Pneumocystis pneumonia prevention in renal transplant recipients, reported adverse drug reactions may limit use and increase reliance on costly and less effective alternatives, often aerosolized pentamidine. We report our experience implementing a protocolized approach to trimethoprim-sulfamethoxazole adverse drug reaction assessment and rechallenge to optimize prophylaxis in this patient cohort. We retrospectively reviewed 119 patients receiving Pneumocystis pneumonia prophylaxis prior to and after protocol implementation. Forty-two patients (35%) had 48 trimethoprim-sulfamethoxazole adverse drug reactions documented either at baseline or during the prophylaxis period, of which 83% were non-immune-mediated and 17% were immune-mediated.
| INTRODUCTION
While trimethoprim-sulfamethoxazole (TMP-SMX) is considered firstline therapy for Pneumocystis jirovecii pneumonia (PJP) prevention in renal transplant recipients (RTRs), aerosolized pentamidine (AP) is frequently used as an alternative due to patient-reported TMP-SMX adverse drug reactions (ADRs). In this context, dapsone is also often avoided due to perceived antibiotic sulfonamide cross-reactivity. 1 Although atovaquone, also, is recommended as a second-2 or thirdline alternative, 3 it is often not used due to cost. 4 The additional costs and adverse effects of AP, 5, 6 as well as the superior efficacy of TMP-SMX, 7 highlight the need to improve the uptake of selective TMP-SMX rechallenge. We report our experience implementing a protocolized approach to TMP-SMX ADR management to optimize PJP prophylaxis in RTRs.
Abbreviations: ADRs, adverse drug reactions; AP, aerosolized pentamidine; MPE, maculopapular exanthem; PJP, Pneumocystis jirovecii pneumonia; RTRs, renal transplant recipients; SeCr, serum creatinine; TMP-SMX, trimethoprim-sulfamethoxazole. 
| MATERIALS AND METHODS

| RESULTS
A total of 166 RTRs were prescribed PJP prophylaxis during the study period, of which 119 (208 courses) were followed up at Austin Health and included in the study. The majority of patients were male (66%), having undergone their first transplant (91%), with a median ageadjusted Charlson comorbidity score of 4 (interquartile range [IQR]:
3, 6) ( Table 1) . IgA nephropathy 23 (19) Polycystic kidney disease 13 (11) Reflux nephropathy 11 (9) Focal segmental glomerulosclerosis 10 (9) Glomerulonephritis (unspecified) 8 (7) Unknown cause 4 (3)
ANCA vasculitis 4 (3)
Systemic lupus erythematosus 2 (2)
Renal calculi 2 (2)
Anti-glomerular basement membrane disease 2 (2)
Other
(9)
Indication for PJP prophylactic course Type-A ADR are typically non-immune-mediated dose-dependent effects (eg gastrointestinal upset, serum creatinine rise). c Type-B ADRs are typically immune-mediated unpredictable reactions that can be both immediate (IgE mediated) or delayed (T cell-mediated). These delayed T cell-mediated reactions can range from mild maculopapular exanthems (MPE) to severe cutaneous adverse drug reactions (SCAR).
| DISCUSSION
Although limited by a short study period and cohort size, our findings suggest that selective TMP-SMX rechallenge is a safe and effective method of optimizing PJP prophylaxis in RTRs, similar to the human immunodeficiency virus setting. 23 The introduction of a standard approach to TMP-SMX ADR assessment and rechallenge resulted in an increase in TMP-SMX utilization and reduction in AP, including associated hospital costs, and should be considered to optimize RTR PJP prophylaxis in transplant units with appropriate expertise.
